Press releases

Read more:

Search
Categories

2022

Nanologica AB has signed a credit line of up to MSEK 50 with the company's main owner Flerie Invest AB. The aim is to cover the company's temporary...

2021

The option program 2021/24 for Nanologica AB resolved by the Annual General Meeting 2021 has now been implemented. The program was subscribed at 100 percent...
2021-12-06 10:13 Nanologica Recruits VP Chromatography Regulatory MAR
Nanologica has recruited Katarina Alenäs as VP Chromatography to lead Nanologica's sales organization within Chromatography globally. As sales...
In accordance with the decision taken at the annual general meeting on May 27, 2021, the three largest shareholders as of September 30, 2021 have been...
2021-09-17 11:15 Nanologica Closes NIC-001 Regulatory MAR
Nanologica AB has decided to close the project with the drug candidate NIC-001 for the treatment of gastroparesis before the planned clinical study begins...
Nanologica has recruited Gary Pitcairn as Chief Scientific Officer as part of the strategy to increase the focus on inhalation and respiratory diseases...
Nanologica has completed the first study within the tox program for the inhalation platform NLAB Spiro®. The program now continues with further studies...
In Nanologica's stock option program 2018/21 exercise of rights in Nanologica’s stock option program has increased the number of shares in the...
The Australian Patent Office has granted Nanologica’s patent titled ”A process for manufacturing porous silica particles loaded with at least...
CEO Andreas Bhagwani has privately and through his company Vega Bianca AB divested 323,000 shares in Nanologica AB for private economic reasons. At the...